CelLBxHealth PLC (AIM:CLBX, FRA:DWV) CEO Peter Collins tells Proactive's Stephen Gunnion that a major restructuring — cutting costs by more than £6.6 million and consolidating facilities — has repositioned the business for commercial growth just as demand for circulating tumour cell analysis accelerates. Collins is direct about the opportunity: "The need for circulating tumour cells as an important component of liquid biopsy is reiterated again and again because it provides information that we can't get from the tissue block." The company is building momentum through collaborations with The Royal Marsden, a major US healthcare provider and a global pharmaceutical group, while expanding its pipeline ahead of key oncology conferences, including The American Society of Clinical Oncology (ASCO). The long-term ambition is for CTC analysis to become part of standard cancer care diagnostic workflows. Watch the full interview for insights into CelLBxHealth’s commercial strategy, partner...